1. Home
  2. STAA vs NTLA Comparison

STAA vs NTLA Comparison

Compare STAA & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • STAA
  • NTLA
  • Stock Information
  • Founded
  • STAA 1982
  • NTLA 2014
  • Country
  • STAA United States
  • NTLA United States
  • Employees
  • STAA N/A
  • NTLA N/A
  • Industry
  • STAA Ophthalmic Goods
  • NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • Sector
  • STAA Health Care
  • NTLA Health Care
  • Exchange
  • STAA Nasdaq
  • NTLA Nasdaq
  • Market Cap
  • STAA 1.4B
  • NTLA 1.2B
  • IPO Year
  • STAA N/A
  • NTLA 2016
  • Fundamental
  • Price
  • STAA $27.25
  • NTLA $14.45
  • Analyst Decision
  • STAA Hold
  • NTLA Buy
  • Analyst Count
  • STAA 8
  • NTLA 20
  • Target Price
  • STAA $22.50
  • NTLA $32.30
  • AVG Volume (30 Days)
  • STAA 674.6K
  • NTLA 4.2M
  • Earning Date
  • STAA 10-29-2025
  • NTLA 11-06-2025
  • Dividend Yield
  • STAA N/A
  • NTLA N/A
  • EPS Growth
  • STAA N/A
  • NTLA N/A
  • EPS
  • STAA N/A
  • NTLA N/A
  • Revenue
  • STAA $224,449,000.00
  • NTLA $52,857,000.00
  • Revenue This Year
  • STAA N/A
  • NTLA $8.32
  • Revenue Next Year
  • STAA $27.24
  • NTLA N/A
  • P/E Ratio
  • STAA N/A
  • NTLA N/A
  • Revenue Growth
  • STAA N/A
  • NTLA 14.99
  • 52 Week Low
  • STAA $13.50
  • NTLA $5.90
  • 52 Week High
  • STAA $38.60
  • NTLA $23.76
  • Technical
  • Relative Strength Index (RSI)
  • STAA 57.35
  • NTLA 75.99
  • Support Level
  • STAA $26.98
  • NTLA $10.89
  • Resistance Level
  • STAA $28.13
  • NTLA $12.03
  • Average True Range (ATR)
  • STAA 0.47
  • NTLA 0.81
  • MACD
  • STAA -0.34
  • NTLA 0.23
  • Stochastic Oscillator
  • STAA 17.14
  • NTLA 91.03

About STAA STAAR Surgical Company

Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of its sales are generated from the ophthalmic surgical product segment.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: